Hagop M. Kantarjian, MD; Terry L. Smith, MS; Susan O'Brien, MD; Miloslav Beran, MD, PhD; Sherry Pierce, RN; Moshe Talpaz, MD; The Leukemia Service*
To determine whether a cytogenetic response after interferon-α therapy in patients with chronic myelogenous leukemia is independently associated with improved survival.
274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-α-based programs between 1982 and 1990.
Therapy with daily subcutaneous interferon-α given at 5 × 106 U/m2 body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule.
Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P ≤ 0.01) and of survival outcomes (P ≤ 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001).
Achieving a cytogenetic response with interferon-α therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.
*For members of the Leukemia Service, see Appendix.
Kantarjian HM, Smith TL, O'Brien S, et al, The Leukemia Service*. Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-α Therapy. Ann Intern Med. 1995;122:254–261. doi: https://doi.org/10.7326/0003-4819-122-4-199502150-00003
Download citation file:
Published: Ann Intern Med. 1995;122(4):254-261.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use